Home›Screener›KYMR›Profile
D
38/100

Kymera Therapeutics

KYMRProtein Degradation
← Signals View
📋
Analyst Summary
✓ VERIFIED2026-04-11

Kymera Therapeutics (KYMR) is the lead sponsor of 3 active clinical trials listed on ClinicalTrials.gov[3], including 2 Phase 2[1], 1 Phase 1[2].

KYMR has 5 Form 4 insider filings recorded at the SEC in the past 30 days[4].

Sources

  1. ClinicalTrials.gov (2026-04-11) ↗
  2. ClinicalTrials.gov (2026-04-11) ↗
  3. ClinicalTrials.gov (2026-04-11) ↗
  4. SEC EDGAR · 0001815442 (2026-04-11) ↗
🔬
Clinical Trials
3
NCT07217015Atopic Dermatitis
Source ↗
clinicaltrials_gov · Retrieved 2026-04-11
NCT07323654Eosinophilic Asthma
Source ↗
clinicaltrials_gov · Retrieved 2026-04-11
NCT07412288Healthy Participants
Source ↗
clinicaltrials_gov · Retrieved 2026-04-11
👤
Insider Activity
1
5 filings
Source ↗
sec_edgar · Retrieved 2026-04-11
Not financial advice. BiotechSigns profiles are AI-generated from verified public sources (ClinicalTrials.gov, SEC EDGAR) and are for informational purposes only. Always do your own due diligence before making investment decisions.
Score Breakdown
Score Trend
2026-04-132026-06-02
Signal Summary
PDUFA Dates0
Insider Filings1
Clinical Trials1
Sector Peers (Protein Degradation)
GLUEMonte Rosa Therapeutics
D
NRIXNurix Therapeutics
D
ARVNArvinas Inc
F
Data Provenance
cik1 verified
clinical trial3 verified
insider buy1 verified
trial count3 verified
Every claim backed by source URL from ClinicalTrials.gov or SEC EDGAR